



The Role of SOX Transcription Factors in Cancer

Guest Editors:

Dr. Philippe Blache

Institut de Recherche en
Cancérologie de Montpellier
(IRCM), University of Montpellier,
ICM, INSERM U1194, Montpellier,
France

Dr. Corinne Prévostel

Institut de Recherche en
Cancérologie de Montpellier
(IRCM), University of Montpellier,
ICM, INSERM U1194, Montpellier,
France

Deadline for manuscript
submissions:

closed (30 September 2021)

Message from the Guest Editors

SOX transcription factors contain a high mobility group (HMG) domain, a conserved amino acid sequence that was originally identified in Sry, a transcription factor that is essential for male sex determination. The SOX family comprises more than 20 members and is recognized as a key element in the development of many organs. It is now clear that SOX proteins also play important roles in the development of many human cancers. Some SOX are oncogenes, others are tumor suppressors, and others can be either oncogenes or tumor suppressors depending on the context. In this Special Issue of *Cancers*, we intend to highlight the complex, paradoxical, and fascinating roles of SOX in several types of cancer. We aim to cover both fundamental and clinical aspects of this field in order to provide an overview of the mechanisms of action of SOX transcription factors and their clinical potential in the management of human cancers.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)